RALEIGH, N.C., Nov. 18 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR), today announced that it completed a $3.15 million credit
facility with NationsBank, N.A.  The proceeds will be used to finance
leasehold improvements and equipment for the Company's new 50,000
square foot facility.  The Company plans to relocate and expand its
manufacturing, research and development and administrative functions to this
facility during the first quarter of 1998.
    "We are pleased to have NationsBank participate in the future of Closure
Medical.  This represents the first significant debt instrument for our
company and reflects a commitment by NationsBank to participate in the
evolution of an emerging technology entity such as Closure," said J. Blount
Swain, Chief Financial Officer.
    CLOSURE Medical develops, commercializes and manufactures medical tissue
cohesive products based on its proprietary cyanoacrylate technology.
CLOSURE's nonabsorbable tissue cohesive products may be used to replace
sutures and staples for certain topical wound closure applications, while its
absorbable tissue cohesive products can potentially be used as surgical
sealants and tissue cohesives for internal wound closure and management.
Currently marketed tissue cohesive products include Octyldent(R), used as an
adjunct in the treatment of adult periodontal disease, Nexaband(R), a line of
topical tissue cohesives used in veterinary wound closure and management and
Dermabond(TM), a nonabsorbable cohesive used for certain topical wound closure
applications.
    This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements.  These factors
include, but are not limited to the early stage of commercialization of the
Company products; the need for regulatory approval and effects of governmental
regulation; technological uncertainties; dependence on marketing partners; and
dependence on patents and trade secrets, as well as those detailed in the
Company's Annual Report on Form 10-K for the year ended December 31, 1996
filed with the Securities and Exchange Commission.

Link to this page: